- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.09. | Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AstraZeneca, GPCR Lead Clinical Trials | 1.147 | AFX News | NEW BRUNSWICK (dpa-AFX) - Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.Notable... ► Artikel lesen | |
| 08.09. | HCW Biologics schließt Vertriebsvereinbarung mit Akron Biotech | 3 | Investing.com Deutsch | ||
| 08.09. | HCW Biologics signs distribution deal with Akron Biotech | 3 | Investing.com | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 08.09. | HCW Biologics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 08.09. | HCW Biologics Inc.: HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells | 3 | GlobeNewswire (USA) | ||
| 02.09. | HCW Biologics Inc.: HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment | 1 | GlobeNewswire (USA) | ||
| 28.08. | HCW Biologics Inc. - S-1/A, General form for registration of securities | 5 | SEC Filings | ||
| 25.08. | HCW Biologics Inc.: HCW Biologics' TGF-ß Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells | 1 | GlobeNewswire (USA) | ||
| 20.08. | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc.: HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results | 405 | GlobeNewswire (Europe) | MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| 14.08. | HCW Biologics Inc. - 10-Q/A, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.07. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.07. | HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering | 590 | GlobeNewswire (Europe) | MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion... ► Artikel lesen | |
| 30.06. | HCW Biologics regains Nasdaq compliance, plans stock split | 1 | Investing.com | ||
| 30.06. | HCW Biologics regains Nasdaq compliance | 1 | Seeking Alpha | ||
| 30.06. | HCW Biologics Inc.: HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter | 205 | GlobeNewswire (Europe) | MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative... ► Artikel lesen | |
| 26.06. | HCW Biologics Commences 1-for-6 Reverse Stock Split | 1 | RTTNews | ||
| 26.06. | HCW Biologics executes 1-for-6 reverse stock split for Nasdaq | 2 | Investing.com |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CELLECTAR BIOSCIENCES | 2,400 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,260 | -1,89 % | Onco-Innovations Ltd: Onco-Innovations issues 860,168 shares for debt | ||
| CEL-SCI | 1,290 | 0,00 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,768 | -1,54 % | Moleculin Biotech, Inc. - 8-K, Current Report | ||
| PDS BIOTECHNOLOGY | 0,764 | +4,09 % | PDS Biotechnology Corporation: PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors | Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation... ► Artikel lesen | |
| GEOVAX LABS | 0,380 | -0,78 % | EQS-News: GeoVax, Inc.: GeoVax Confirms Bundibugyo Ebola Vaccine Construct | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax Confirms Bundibugyo Ebola Vaccine Construct 16.09.2026 / 14:37 CET/CEST
The issuer is solely responsible for the content... ► Artikel lesen | |
| COCRYSTAL | 1,030 | +3,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| LISATA THERAPEUTICS | 1,570 | +3,29 % | XFRA 8NE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLISATA THERAP.INC.DL-... ► Artikel lesen | |
| DECOY THERAPEUTICS | 2,820 | -0,35 % | Aktionäre von Decoy Therapeutics stimmen Ausgabe von Optionsscheinen und Aktienreduzierung zu | ||
| JASPER THERAPEUTICS | 0,614 | -3,17 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Key Regulatory and Clinical Appointments | Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 2,750 | -1,79 % | Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion... ► Artikel lesen | |
| VISTAGEN THERAPEUTICS | 0,240 | +2,65 % | Vistagen Therapeutics, Inc. - 8-K, Current Report | ||
| IN8BIO | 0,905 | -3,21 % | IN8bio, Inc: IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development | Renowned ?d T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they... ► Artikel lesen | |
| METAVIA | 1,580 | 0,00 % | MetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction | Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support... ► Artikel lesen | |
| EVAXION | 3,200 | +0,63 % | Evaxion applies its AI-Immunology platform in autoimmune diseases | Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology to target underlying pathologiesThe unique capabilities... ► Artikel lesen |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+5,13 %) liegt der Kurs bei 2,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.